CORT Corcept Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CORT

Price (delayed)

$25.56

Market cap

$2.63B

P/E Ratio

29.05

Dividend/share

N/A

EPS

$0.88

Enterprise value

$2.52B

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® ...

Highlights
Corcept Therapeutics's debt has shrunk by 87% YoY and by 24% QoQ
The revenue rose by 13% year-on-year and by 5% since the previous quarter
The company's equity rose by 10% QoQ but it fell by 2.5% YoY
The quick ratio has dropped by 60% year-on-year and by 25% since the previous quarter
The P/E is 34% more than the 5-year quarterly average of 21.6 and 14% more than the last 4 quarters average of 25.5
Sector: Healthcare
Industry: Biotechnology
Website: http://www.corcept.com
Peers: JNJ BMY ESPR LLY

Key stats

What are the main financial stats of CORT
Market
Shares outstanding
103.08M
Market cap
$2.63B
Enterprise value
$2.52B
Valuations
Price to earnings (P/E)
29.05
Price to book (P/B)
5.68
Price to sales (P/S)
5.79
EV/EBIT
25.85
EV/EBITDA
25.21
EV/Sales
5.61
Earnings
Revenue
$450.03M
EBIT
$97.59M
EBITDA
$100.07M
Free cash flow
$154.37M
Per share
EPS
$0.88
Free cash flow per share
$1.51
Book value per share
$4.5
Revenue per share
$4.41
TBVPS
$5.82
Balance sheet
Total assets
$594.02M
Total liabilities
$132.34M
Debt
$225,000
Equity
$461.68M
Working capital
$309.65M
Liquidity
Debt to equity
0
Current ratio
3.54
Quick ratio
3.2
Net debt/EBITDA
-1.11
Margins
EBITDA margin
22.2%
Gross margin
98.6%
Net margin
20.2%
Operating margin
21.8%
Efficiency
Return on assets
15.7%
Return on equity
19%
Return on invested capital
29.9%
Return on capital employed
20.7%
Return on sales
21.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CORT stock price

How has the Corcept Therapeutics stock price performed over time
Intraday
0.43%
1 week
0.87%
1 month
-6.24%
1 year
0%
YTD
25.85%
QTD
-6.18%

Financial performance

How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$450.03M
Gross profit
$443.94M
Operating income
$98.11M
Net income
$90.87M
Gross margin
98.6%
Net margin
20.2%
The operating margin has contracted by 32% YoY and by 6% from the previous quarter
Corcept Therapeutics's net margin has decreased by 31% YoY and by 8% QoQ
Corcept Therapeutics's operating income has decreased by 23% YoY
CORT's net income is down by 22% YoY and by 3.6% QoQ

Growth

What is Corcept Therapeutics's growth rate over time

Valuation

What is Corcept Therapeutics stock price valuation
CORT P/E details
P/E
29.05
P/B
5.68
P/S
5.79
EV/EBIT
25.85
EV/EBITDA
25.21
EV/Sales
5.61
The P/E is 34% more than the 5-year quarterly average of 21.6 and 14% more than the last 4 quarters average of 25.5
The EPS has declined by 19% year-on-year
The stock's price to book (P/B) is 16% more than its 5-year quarterly average of 4.9 and 14% more than its last 4 quarters average of 5.0
The company's equity rose by 10% QoQ but it fell by 2.5% YoY
The revenue rose by 13% year-on-year and by 5% since the previous quarter
CORT's P/S is 3.5% below its 5-year quarterly average of 6.0 but 3.4% above its last 4 quarters average of 5.6

Efficiency

How efficient is Corcept Therapeutics business performance
CORT's return on assets is down by 35% year-on-year and by 6% since the previous quarter
The return on sales has declined by 32% year-on-year and by 6% since the previous quarter
The return on equity has declined by 31% year-on-year and by 3.1% since the previous quarter
CORT's ROIC is down by 12% year-on-year but it is up by 4.5% since the previous quarter

Dividends

What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CORT.

Financial health

How did Corcept Therapeutics financials performed over time
The total liabilities has soared by 121% YoY and by 28% from the previous quarter
The quick ratio has dropped by 60% year-on-year and by 25% since the previous quarter
Corcept Therapeutics's debt is 100% lower than its equity
Corcept Therapeutics's debt has shrunk by 87% YoY and by 24% QoQ
The company's equity rose by 10% QoQ but it fell by 2.5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.